Weekend Unlimited Inc. (CSE:POT) (FSE: 0OS1) (OTCMKTS:WKULF) (“Weekend” or the “Company”) having announced a Letter of Intent on 1 November 2018 to acquire R&D Pharma’s Jamaican interests, has now entered into a definitive agreement with R&D Pharma, which is anticipated to close next week.
R&D Pharma (“RDP”) is a Canadian company building a vertically integrated medical cannabis business in Jamaica. RDP has secured a Tier-3 Cultivator’s License, which allows for full cultivation of cannabis plants on land of over 5 acres, which in this case applies to the 98-acre RDP property.
R&D Pharma Highlights include:
- Approved Tier-3 cultivators license
- Medical tourism in Jamaica, plus phenotyping with Jamaican sativas, to brand and export internationally recognized strains, extracts, and infused products
- Will be a significant exporter of branded full spectrum extracts as well as extracted cannabinoids from one of world’s lowest cost geographies for growing cannabis
“Upon signing this deal, we are excited to accelerate operations in Jamaica. There has been tremendous work accomplished on the property by the team on the ground and the cultivation results have been impressive in both quality and economically,” noted Mr. Paul Chu, Weekend Unlimited President and CEO.
About Weekend Unlimited Inc.
Weekend Unlimited is capitalizing on its vast industry relationships to establish a lifestyle brand featuring premium products and delivering life’s highest moments. The company aggregates and scales small to medium brands, primarily in the categories of flower, extracts and edibles. Weekend Unlimited brands have best of class operations, distribution and strong revenue trajectories, making them ideal candidates for the deployment of capital and expertise through access to technologies, infrastructure and centralized systems. Learn more at www.weekendunlimited.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
For further information, please contact:
Mr. Paul Chu, President and CEO
Telephone: +1(236) 317-2812 – Toll free 1(888) 556-9656
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
The product will include polyphenols known to have significant health benefits.